What changed for Fibromyalgia
A plain English summary of what recently moved in the public data Voxsanity tracks for Fibromyalgia. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 119 to 118 (-1)
- Trials on record 1,252 to 1,254 (+2)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Fibromyalgia yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 35 trials tracked for Fibromyalgia that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04115033 · results posted 27 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04115033) looked at a treatment called Cranial Electrotherapy Stimulation (CES) — a device that delivers a very mild electrical current to the head — in people with fibromyalgia, a condition involving widespread pain. A total of 48 people were enrolled: 25 in the group using the real CES device and 23 in a "sham" (inactive/pretend device) group for comparison. Of those, 17 in the real-device group and 16 in the sham group completed the study. The trial measured pain scores, physical function, brain connectivity patterns on...
-
NCT02589275 · results posted 11 December 2024
According to the results reported on ClinicalTrials.gov, this trial involved 375 people across two groups. One group (177 people) had previously received the active treatment, TNX-102 SL, in an earlier study and continued on it here — referred to as the TNX-TNX group. The other group (198 people) had previously received a placebo and then switched to the active treatment in this open-label extension study — referred to as the PBO-TNX group. An open-label extension means all participants knew they were receiving the active treatment. The study tracked whether participants experienced any new ad...
-
NCT04059042 · results posted 15 December 2023
According to the results reported on ClinicalTrials.gov, this trial involved 10 people in total — 5 in a "Music" group and 5 in a "Nature Sounds" group. Nine participants completed the study (4 in the Music group and 5 in the Nature Sounds group), with one person in the Music group not finishing. The trial was measuring two things related to how people experience pain: "pain threshold summation" (roughly, how much worse pain feels when a stimulus is repeated 10 times in a row compared to just once) and "pain tolerance" (the amount of physical pressure at which a person rates their pain at 70 o...
-
NCT05005351 · results posted 1 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT05005351) involved 67 people with fibromyalgia, split into two groups. Thirty-nine participants were assigned to a digital program based on Acceptance and Commitment Therapy (ACT) — a type of structured psychological approach delivered online — and 28 were assigned to a digital symptom tracker. The trial was measuring how fibromyalgia severity and participants' own sense of change compared between the two groups over 12 weeks. Almost all participants who started the trial completed it (37 out of 39 in the ACT group, and 27...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01693692 · results posted 4 March 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 392 people across three groups: one group received a placebo (a dummy treatment with no active ingredient), and two groups received different amounts of a drug called TD-9855. The trial was measuring how fibromyalgia — a condition causing widespread pain — responded across several measures, including daily pain levels, overall impact on daily life, and participants' own sense of whether their condition had changed. The reported data shows that the primary measure was the percentage change in pain scores, rated on a s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03056690 · results posted 3 March 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03056690) enrolled 186 people in total — 95 in the placebo group (a dummy treatment with no active ingredient) and 91 in the ASP0819 15 mg group. The trial was measuring changes in daily pain levels over 8 weeks using a standard 0–10 pain rating scale (where 0 means no pain and 10 means the worst pain imaginable), as well as tracking unwanted health events and monitoring for any thoughts or behaviours related to suicide throughout the study period. The reported data shows that, on average, participants in the placebo grou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03497585 · results posted 17 December 2020
According to the results reported on ClinicalTrials.gov, this trial tested an "Activity Pacing Framework" — a structured programme designed to help people with chronic pain or fatigue learn strategies for managing their daily activities across five areas: adjusting activities, keeping activities consistent, planning activities, accepting limitations, and progressing activities gradually. A total of 112 people started the trial, 57 completed it, and 55 did not complete it. There was only one group in this trial, meaning everyone received the same programme; there was no comparison group. The m...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02187159 · results posted 9 November 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,270 people across four groups to study treatments for fibromyalgia — a condition involving widespread pain and fatigue. Participants were randomly assigned to receive either a placebo (a dummy treatment with no active ingredient), pregabalin 150 mg twice daily, DS-5565 15 mg once daily, or DS-5565 15 mg twice daily. The main thing being measured was how much each person's daily pain score changed over 13 weeks, rated on a scale from 0 (no pain) to 10 (worst possible pain). Between 221 and 249 people in each group co...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03008837 · results posted 27 July 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03008837) enrolled 21 people with fibromyalgia — 12 in a group receiving a treatment called PENFS (a type of nerve stimulation applied to the ear) and 9 receiving standard therapy. By the end of the study, 9 people in the PENFS group and 5 in the standard therapy group had completed it. The trial was measuring whether a brain-scanning technique called functional connectivity MRI (fcMRI — a scan that looks at how different parts of the brain communicate with each other) could detect changes in brain activity related to pain...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02234583 · results posted 23 July 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 2,088 participants in total — 847 in a once-daily dose group and 1,241 in a twice-daily dose group — of whom 434 and 685 respectively completed the study. The trial was testing a medicine called DS-5565 (taken either once or twice a day) and was measuring things like daily pain levels, sleep disruption, mood, and overall quality of life over 52 weeks (about one year). Participants were split into two broad categories: "rollover" participants who had been in an earlier related study, and "de novo" participants who were...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03825393 · results posted 7 April 2020
According to the results reported on ClinicalTrials.gov, this study involved 200 people in total — 100 people diagnosed with fibromyalgia and 100 people without the condition who served as a comparison (control) group. All 200 participants completed the study with no dropouts reported. The study was measuring sleep quality, iron storage levels in the blood (ferritin), and the impact of fibromyalgia on daily life, mood, and anxiety in people with fibromyalgia compared to those without it. The reported data shows that people in the fibromyalgia group had an average score of 8.3 on the Pittsburg...
-
NCT01797263 · results posted 24 February 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 256 adults with fibromyalgia — 129 assigned to a yoga programme and 127 assigned to a structured exercise programme. The trial was measuring the overall impact of fibromyalgia on participants' lives, using a questionnaire called the Fibromyalgia Impact Questionnaire Revised (FIQR). The main measurement point was at three months, with further check-ins at six and nine months to see whether any changes lasted. By the end of the study, 92 people in the yoga group and 87 in the structured exercise group had completed it....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03619889 · results posted 24 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 74 people in total — 37 in a "sham simulation" group (a dummy/inactive version of the treatment, used as a comparison) and 37 in a "Manual Pressure Release Technique" group (a hands-on physical therapy approach targeting muscle trigger points). Two participants in the sham group did not complete the study, while everyone in the treatment group finished. The trial was measuring changes in pain levels, jaw opening, neck disability, and several psychological measures across three time points: before treatment, immediatel...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00932360 · results posted 10 January 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT00932360) enrolled 43 participants in total across six groups, each receiving the three study conditions — active TENS (a device that sends mild electrical pulses through the skin), placebo TENS (a sham version of the device), and no treatment — in a different order. There was a one-week "washout" break between each condition to allow any effects to fade before the next one began. Two participants dropped out during the first washout period, so 41 people completed all three stages. The trial was measuring changes in pain a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00447083 · results posted 13 November 2018
According to the results reported on ClinicalTrials.gov, this trial looked at whether exposure to UVB light (a type of ultraviolet light) had any effect on pain, compared to a non-UVB exposure used as a comparison. The trial ran in two phases. In Phase I, 19 people took part (10 in one group, 9 in another), and all 19 completed that phase. In Phase II, 16 people took part (8 in each group), and 14 of those 16 completed the phase — one person from each group did not finish. The trial measured pain using an 11-point scale, where 0 meant no pain and 10 meant the worst possible pain. The reported...
-
NCT03039088 · results posted 19 September 2018
According to the results reported on ClinicalTrials.gov, this trial involved 508 people in total — 192 who had been identified as having fibromyalgia, and 316 who had not. All participants completed the study with no drop-outs recorded. The trial was looking at whether having fibromyalgia affected how people responded to a type of medication called TNF alpha blockers (a group of treatments used in certain inflammatory conditions). Response to treatment was measured using something called the BASDAI50 — this is a scoring tool where a 50% improvement in a patient's symptom score is counted as a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01981096 · results posted 10 September 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 young people with fibromyalgia, split into two groups of 20. One group received a programme called Fibromyalgia Integrative Training, and the other received Cognitive Behavioral Therapy (a talking-based approach to managing thoughts and feelings). The trial measured three things: average pain intensity over the past week, how much difficulty participants had with everyday physical and social activities (called functional disability), and depressive symptoms. By the end of the study, 17 participants in the Fibromyal...
-
NCT00523302 · results posted 11 July 2018
According to the results reported on ClinicalTrials.gov, this trial involved 20 people with fibromyalgia, split evenly into two groups of 10. One group received active Transcranial Magnetic Stimulation (TMS — a non-invasive procedure that uses magnetic pulses directed at the brain), and the other received a "sham" version, meaning it mimicked the procedure without delivering real stimulation. All 20 participants completed the study. The trial was measuring three things across multiple time points: average pain levels, the overall impact of fibromyalgia on daily functioning, and symptoms of dep...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02500628 · results posted 3 January 2018
According to the results reported on ClinicalTrials.gov, this trial involved two groups of participants: 38 people with fibromyalgia and 23 people who were taking antipsychotic medication. All 61 participants completed the study — none dropped out. The trial was measuring how a single dose of metformin (a medication commonly used for diabetes) affected the heart's rhythm patterns, specifically something called heart rate variability. This refers to the tiny natural changes in the time between heartbeats, which can reflect how the body's nervous system is functioning. Measurements were taken be...
-
NCT02015234 · results posted 7 July 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT02015234) involved people with fibromyalgia and looked at a medication called TNX-102 SL (a tablet placed under the tongue at bedtime). A total of 158 people took part — 79 in a group that started on a placebo (a dummy tablet) before switching to TNX-102 SL, and 79 who took TNX-102 SL throughout. Of those, 43 and 54 people respectively completed the full study period. The trial's main focus was on tracking newly emerging unwanted events (side effects or health changes noticed after starting treatment) over 12 months, and i...
-
NCT02052414 · results posted 9 October 2015
According to the results reported on ClinicalTrials.gov, this trial enrolled 34 participants, all of whom received a medication called Gralise (an extended-release form of gabapentin). The trial was measuring how fibromyalgia affected participants over approximately 15 weeks — including their pain levels, sleep, and overall wellbeing — using several standard questionnaires and rating scales. Of the 34 people who started the trial, 17 completed it, and 17 did not complete it. The reported data shows the following numbers across five visits (baseline, then roughly every 4 weeks during treatment...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01108731 · results posted 15 October 2014
According to the results reported on ClinicalTrials.gov, this trial involved 34 people in total — 17 who took a drug called milnacipran and 17 who took a placebo (a dummy treatment with no active ingredient). Of those, 13 in each group completed the trial, and 4 in each group did not finish. The trial was measuring three things: levels of a chemical called lactate in the brain (using a brain scanning technique), how quickly and accurately people responded in a computer-based attention test, and how much widespread pain people reported on a scale of 0 to 10. The reported data shows that, for b...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00928720 · results posted 13 August 2014
According to the results reported on ClinicalTrials.gov, this trial (NCT00928720) enrolled 57 people in total across three groups: 19 received an active CES (cranial electrotherapy stimulation) device, 20 received a sham (inactive) version of the same device, and 18 received usual care alone. By the end of the study, 17, 14, and 15 participants respectively had completed the trial. The trial was measuring pain intensity as its main focus, along with several other things including fatigue, sleep disturbance, depression, perceived stress, and overall functioning — all commonly affected in condit...
-
NCT00115804 · results posted 15 February 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 6 participants, all of whom received the medication fluoxetine. Four participants completed the study, while 2 did not finish. The trial was measuring pain severity and a range of other outcomes in children, including how much their daily activities were affected, their mood, and how they and their clinicians rated their overall condition and any improvement over time. The reported data shows that on the main measure — average pain severity, rated on a scale from 0 (no pain) to 100 (severe pain) — participants scored...
-
NCT00830167 · results posted 1 June 2012
According to the results reported on ClinicalTrials.gov, this trial enrolled 498 people — 248 in a placebo (dummy treatment) group and 250 in a pregabalin group. The trial was measuring pain levels in participants, using an 11-point scale where 0 means no pain and 10 means the worst possible pain. It also tracked how participants felt their overall condition had changed, and looked at several aspects of sleep quality, including sleep disturbance, snoring, waking up short of breath or with a headache, and the total amount of sleep each night. The reported data shows that, for the main pain mea...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00830128 · results posted 14 February 2012
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 participants, all of whom received the study medicine pregabalin. By the end of the study, 87 participants had completed it, while 19 did not finish. The trial was primarily focused on tracking any unwanted medical events (called adverse events) that occurred during treatment, including serious ones — such as events leading to hospitalisation, life-threatening situations, or death. Secondary measurements looked at changes in self-reported pain levels and several aspects of sleep quality. The reported data shows t...
-
NCT01077375 · results posted 26 January 2012
According to the results reported on ClinicalTrials.gov, this trial (NCT01077375) involved 107 participants in total — 21 in the placebo group and 86 in the milnacipran group. The trial was measuring two main things: first, how many participants reported feeling "very much improved" or "much improved" on a simple self-rated scale called the Patient Global Impression of Change (PGIC) at week 13; and second, how much participants' pain scores changed over the same period, using a pain scale running from 0 (no pain) to 100 (worst possible pain). Not everyone finished the trial — 11 out of 21 plac...
-
NCT00087555 · results posted 10 January 2012
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called sodium oxybate (brand name Xyrem) in people with fibromyalgia — a condition involving widespread pain and other symptoms. A total of 195 people started the trial and were split into three groups: one group received a placebo (a dummy treatment with no active ingredient), one received a 4.5g dose of Xyrem, and one received a 6.0g dose. The trial ran for 8 weeks and was measuring whether participants improved across three self-reported areas: their pain level, their overall fibromyalgia impact on da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00423605 · results posted 20 October 2011
According to the results reported on ClinicalTrials.gov, this trial enrolled 560 people, all of whom received Xyrem (sodium oxybate) at doses ranging from 4.5 grams to 9.0 grams. Of those who started the trial, 319 people completed it, while 241 did not finish. The trial was set up to track and record any unwanted or unexpected health events (called adverse events) that participants experienced while taking the medication. The reported data shows that the only outcome measure recorded was the number of participants who reported at least one adverse event during the study. According to the res...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00793520 · results posted 1 July 2010
According to the results reported on ClinicalTrials.gov, this trial (NCT00793520) was a crossover study, meaning participants were assigned to receive either the medication milnacipran followed by a placebo, or a placebo followed by milnacipran. The trial was measuring two things: firstly, whether the amount of pressure needed to cause a medium level of pain changed over the course of treatment (the primary measure); and secondly, whether a pain-processing response in the body — known as Diffuse Noxious Inhibitory Control, or DNIC, which is essentially the body's natural ability to dampen pain...
See all 35 reported results for Fibromyalgia
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, fibromyalgia currently receives a moderate amount of public research funding from the United States government, which is the largest single funder of biomedical research in the world. Importantly, that funding has been falling year on year, which suggests that fibromyalgia is not currently a growing priority within the publicly funded research system. For patients, t...
See the full Fibromyalgia page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.